Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol in Adenylosuccinate Lyase Deficiency (ADSL)
NCT03776656Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allopurinol in Adenylosuccinate lyase deficiency (ADSL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Vineland II Adaptive Behavior Scale Composite Total Score at 12 months. Started Oct 2019; status: completed.
02
Drugs
allopurinol
03
Conditions
Adenylosuccinate lyase deficiency (ADSL)
Beyond the preview
Go deeper on NCT03776656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776656.